retatrutide phase 2 trial new england journal of medicine In the ATTAIN-1 3, randomized trial, the use orforglipron, an oral glucagon-like peptide-1 receptor agonist, led to significant mean body-weight reductions in patients with obesity, as compared with placebo. Full retatrutide phase 2 trial new
Pay in 4 interest-free payments of $6.51 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 9 - Nov 14


























